It's Time To Consider Leveraged Healthcare ETFs

For traders using leveraged sector exchange-traded funds, one key to successfully using these products in the short-term fashion in which they are intended is to treat leveraged ETFs as event-driven trades.

Those events include earnings announcements, mergers and acquisitions headlines and, for leveraged healthcare ETFs, clinical trial data reports and industry conferences.

What Happened

With one of the industry's marquee conferences recently ending, traders may want to consider the Direxion Daily Healthcare Bull 3X Shares CURE and the Direxion Daily S&P Biotech Bull 3X Shares LABU.

The American Society of Clinical Oncology Annual Meeting ended this week, which could bring CURE and LABU into focus for active traders.

CURE attempts to deliver triple the daily returns of the Health Care Select Sector Index (IXVTR) while LABU looks to deliver triple the daily returns of the equal-weight S&P Biotechnology Select Industry Index (SPSIBITR).

Why It's Important

“The meeting came at an interesting time for the healthcare market,” said Direxion in a recent note. “Against a backdrop of several Congressional hearings on the rising costs of drugs in this country, healthcare and biotech stocks have underperformed the overall market in 2019.”

LABU is often one of the most volatile bullish leveraged funds in the Direxion stable, which is to be expected when pairing leverage and biotechnology. Conversely, CURE is usually one of the more docile Direxion leveraged sector funds.

CURE is up 6.65 percent this week while LABU is up 0.79 percent after tumbling 4.87 percent on Thursday.

What's Next

While CURE has been mostly calm in recent days, the leveraged healthcare fund and its biotechnology counterpart LABU could still feel some impact from the ASCO conference.

“Results presented at ASCO may have major ramifications for the market, even as macro events cast their shadow. Last year’s ASCO star, Loxo Oncology, got bought by Eli Lilly in January,” according to Direxion. “And though the long-term picture on the sector will remain cloudy until we get some clarity on how Congress intends to act on drug pricing, one way or the other we’re going to see some volatility this weekend.”

Related Links

Trade The Trade War With This ETF

Take A Chance With This Sector ETF

Posted In: American Society of Clinical Oncology (ASCO)Direxion ETFDirexion InvestmentsBiotechLong IdeasNewsSector ETFsHealth CareEventsTrading IdeasETFs

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.